Literature DB >> 22523304

A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials.

Yimei Li1, Rosemarie Mick, Daniel F Heitjan.   

Abstract

BACKGROUND: Phase II cancer clinical trials commonly employ two-stage designs that incorporate a single interim analysis for lack of efficacy and are designed to achieve specified frequentist properties. The requirement to examine the outcome at a prespecified sample size (SS) can be problematic, because the attained SS often differs from the planned SS.
PURPOSE: We propose to address unplanned SSs achieved at either stage by means of a Bayesian approach that approximately preserves the original design's properties.
METHODS: Our approach translates the rejection rule of the original frequentist design into equivalent statements about the posterior distribution of the response rate and applies this Bayesian criterion to the analysis with any realized SS.
RESULTS: The results demonstrate that our approach approximately maintains operating characteristics of the original frequentist design including type I and type II error rates, probability of early termination, and expected SS under the null hypothesis. LIMITATIONS: Designs attained under this approach may not satisfy target limits for type I error rate and power.
CONCLUSIONS: Our method offers a coherent analysis plan when the attained SS at either stage deviates from that specified in the original design. The price of its flexibility, in terms of erosion of the desired frequentist properties, is modest.

Entities:  

Mesh:

Year:  2012        PMID: 22523304      PMCID: PMC4283461          DOI: 10.1177/1740774512443429

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  23 in total

Review 1.  Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.

Authors:  Matthew S Mayo; Byron J Gajewski
Journal:  Control Clin Trials       Date:  2004-04

2.  On the estimation of the binomial probability in multistage clinical trials.

Authors:  Sin-Ho Jung; Kyung Mann Kim
Journal:  Stat Med       Date:  2004-03-30       Impact factor: 2.373

3.  Bayesian design of single-arm phase II clinical trials with continuous monitoring.

Authors:  Valen E Johnson; John D Cook
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

4.  Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.

Authors:  Nobuyuki Masaki; Tatsuki Koyama; Isao Yoshimura; Chikuma Hamada
Journal:  J Biopharm Stat       Date:  2009-07       Impact factor: 1.051

5.  The bias of the sample proportion following a group sequential phase II clinical trial.

Authors:  M N Chang; H S Wieand; V T Chang
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

6.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

7.  Phase II trials in cancer: present status and analysis methods.

Authors:  Y J Lee
Journal:  Drugs Exp Clin Res       Date:  1986

8.  A bayesian approach to the design of phase II clinical trials.

Authors:  R J Sylvester
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

9.  One-sample multiple testing procedure for phase II clinical trials.

Authors:  T R Fleming
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

10.  Admissible two-stage designs for phase II cancer clinical trials.

Authors:  Sin-Ho Jung; Taiyeong Lee; KyungMann Kim; Stephen L George
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

View more
  4 in total

1.  Suspension of accrual in phase II cancer clinical trials.

Authors:  Yimei Li; Rosemarie Mick; Daniel F Heitjan
Journal:  Clin Trials       Date:  2015-01-07       Impact factor: 2.486

2.  Optimal inference for Simon's two-stage design with over or under enrollment at the second stage.

Authors:  Guogen Shan; John J Chen
Journal:  Commun Stat Simul Comput       Date:  2017-06-20       Impact factor: 1.118

3.  Hypothesis testing for two-stage designs with over or under enrollment.

Authors:  Donglin Zeng; Fei Gao; Kuolung Hu; Catherine Jia; Joseph G Ibrahim
Journal:  Stat Med       Date:  2015-03-25       Impact factor: 2.373

4.  Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.

Authors:  Junjun Zhao; Menggang Yu; Xi-Ping Feng
Journal:  BMC Med Res Methodol       Date:  2015-06-07       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.